Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25377246,half-life,"For the 2.5 mg/kg dose, the median half-life was ~21 h.",Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377246/),h,21,107925,DB08800,Chloropyramine
,25377246,Oral bioavailability,"Oral bioavailability for formulations of PBS, TPGS, Maalox(®), and Pepcid(®) was greatest with TPGS (45 %), followed by Maalox(®) (42 %), Pepcid(®) (37 %), and PBS (30 %).",Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377246/),%,45,107926,DB08800,Chloropyramine
,25377246,Oral bioavailability,"Oral bioavailability for formulations of PBS, TPGS, Maalox(®), and Pepcid(®) was greatest with TPGS (45 %), followed by Maalox(®) (42 %), Pepcid(®) (37 %), and PBS (30 %).",Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377246/),%,42,107927,DB08800,Chloropyramine
,25377246,Oral bioavailability,"Oral bioavailability for formulations of PBS, TPGS, Maalox(®), and Pepcid(®) was greatest with TPGS (45 %), followed by Maalox(®) (42 %), Pepcid(®) (37 %), and PBS (30 %).",Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377246/),%,37,107928,DB08800,Chloropyramine
,25377246,Oral bioavailability,"Oral bioavailability for formulations of PBS, TPGS, Maalox(®), and Pepcid(®) was greatest with TPGS (45 %), followed by Maalox(®) (42 %), Pepcid(®) (37 %), and PBS (30 %).",Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377246/),%,30,107929,DB08800,Chloropyramine
